Archive for the ‘Cancer / Oncology’ Category

U.S. NCI Starts Enrolment In Phase 2 Systemic Melanoma Clinical Trial With REOLYSIN(R)

Wednesday, August 13th, 2008

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced that the U.S. National Cancer Institute (NCI), part of the National Institutes of Health, has started enrolment in a Phase 2 clinical trial for patients with metastatic melanoma using ...

Cancer Cells With A Long Breath: Seeking The Origin Of Brain Tumours In Children

Wednesday, August 13th, 2008

Medulloblastoma is one of the most common and most malignant brain tumours among children and teenagers. These tumours grow very rapidly, and fifty percent of patients in the long term die from the condition. The details of the processes that lead to the growth of these tumours have remained unknown ...

Cancer Doctor Invents Test For New Drugs That Cut Off Tumor's Blood Supply

Wednesday, August 13th, 2008

In the August 11 online edition of the Journal of Internal Medicine reports discovery of the first practical laboratory test to guide the use of new-generation drugs that kill cancer cells by cutting off their blood supply. The new test, called the Microvessel Vascular (MVV) assay, was developed by ...

Scientists Use Old Enemy To Knock Out Cancer

Wednesday, August 13th, 2008

Chemists are pulling cancer onto a sucker punch by getting infected cells to drop their guard - according to research published recently. They are using the metal ruthenium as a catalyst to a cancer-busting reaction which calls up an old cellular enemy - oxidants - as an ally. Cancer adapts ...

VitiGam™ Inhibits Melanoma Growth In A Dose Dependent Manner - Inhibition Of Tumor Growth Is Statistically Significant

Wednesday, August 13th, 2008

GammaCan International, Inc. (OTCBB: GCAN), a developer of proprietary immunotherapies for the treatment of melanoma and other cancers, announced further progress in its VitiGam™ development program. In preparation for its upcoming IND submission for VitiGam™, the Company successfully completed additional experiments using its established mouse melanoma model. These studies demonstrate ...

Blue Cross Blue Shield Of Michigan-American Society Of Clinical Oncology Initiative To Reduce Costs, Improve Patient Care

Wednesday, August 13th, 2008

Blue Cross Blue Shield of Michigan and the American Society of Clinical Oncology are collaborating to collect and analyze treatment information on tens of thousands of people with cancer in Michigan in an effort to improve care and reduce costs, the Detroit News reports. According to BCBS officials, similar initiatives ...

Brain Tumour Origin Identified

Wednesday, August 13th, 2008

Australian and American scientists have identified the origins of the most malignant type of brain tumour in a discovery that could lead to better therapies and improve our understanding of how tumours initiate. The team, led by Professor Brandon Wainwright from the Institute for Molecular Bioscience at the University of ...

Risk Assessment Is Key In Long-Term Breast Cancer Treatment

Wednesday, August 13th, 2008

M. D. Anderson-led team finds breast cancer five-year survivors may benefit from additional therapy.Breast cancer patients and their physicians may make more informed, long-term treatment decisions using risk assessment strategies to help determine probability of recurrence, a research team led by scientists at The University of Texas M. D. Anderson ...

American Airlines Pledges Multi-Milion Breast Cancer Grant To M.D. Anderson

Wednesday, August 13th, 2008

Susan G. Komen for the Cure?, American Airlines and The University of Texas M. D. Anderson Cancer Center are targeting title="Breast Cancer Research Award" alt="Breast Cancer Research Grant">

Researchers Use Old Enemy To Reverse Cancer

Wednesday, August 13th, 2008

Chemists are pulling cancer onto a sucker punch by getting infected cells to drop their guard – according to research published today. They are using the metal ruthenium as a catalyst to a cancer-busting reaction which calls up an old cellular enemy – oxidants – as an ally.Cancer adapts quickly ...

Adenocarcinoma Of The Esophagus Increasing in White Men and Women

Wednesday, August 13th, 2008

The incidence of adenocarcinoma of the esophagus in the United States increased among both white men and women between 1975 and 2004.The overall incidence of esophageal cancer has been climbing in white men, holding steady in white women, and decreasing in black men and women. Previous reports suggested that the ...

Sequential Doxorubicin, Zoledronic Acid Have Strong Anti-Breast Cancer Effect

Wednesday, August 13th, 2008

The use of doxorubicin followed by zoledronic acid reduced tumor size substantially in a mouse model of breast cancer that does not have bone metastases.Zoledronic acid is a bisphosphonate currently used for the treatment of cancer-related bone disease in a variety of malignancies, including breast cancer. Breast cancer patients are ...

Few Pharmacologic Treatments of Cancer-Related Fatigue Available to Patients

Wednesday, August 13th, 2008

There is limited evidence to support the use of methylphenidate and erythropoietin for the treatment of cancer-related fatigue in some patients, according to a systematic review of randomized controlled trials.Cancer-related fatigue is a common problem for patients undergoing treatment and for cancer survivors. However, the underlying causes of the problem ...

Hepatitis B Genotypes and Mutants May Influence Liver Cancer Risk

Wednesday, August 13th, 2008

Infection with hepatitis B virus (HBV) causes liver cancer in some individuals, but not all strains of the virus are associated with the same degree of risk. If confirmed, the newly reported data could help target chemoprevention strategies in the future. Researchers have previously identified eight genotypes of HBV and ...

Newly Discovered Molecular Switch Helps Decide Cell Type In Early Embryo Development - Finding Creates New Path To Study Birth Defects And Cancer

Tuesday, August 12th, 2008

Researchers have discovered a central molecular switch in fruit fly embryos that opens new avenues for studying the causes of birth defects and cancer in humans. Writing about their study in the Aug. 12 Developmental Cell, scientists at Cincinnati Children's Hospital Medical Center determined the switch to be a main ...